<DOC>
	<DOCNO>NCT02402491</DOCNO>
	<brief_summary>Patients undergo percutaneous coronary intervention ( PCI ) in-stent restenosis ( ISR ) enrol . All patient randomize receive either 12 month 24 month dual antiplatelet therapy P2Y12 receptor antagonist addition aspirin , patient continue receive aspirin indefinitely . The primary efficacy end point study incidence composite end point include cause death , myocardial infarction , incidence Academic Research Consortium define definite probable stent thrombosis stroke ( MACCE ) 24 month . The primary safety end point incidence GUSTO moderate severe bleeding .</brief_summary>
	<brief_title>Twelve vs 24 Months Dual Antiplatelet Therapy Patients With Coronary Revascularization In-stent Restenosis</brief_title>
	<detailed_description>The ISR-DAPT Study multicenter , randomize control trial enroll 1000 subject treat percutaneous coronary intervention ( PCI ) in-stent restenosis . All patient randomize receive either 12 month 24 month dual antiplatelet therapy P2Y12 receptor antagonist addition aspirin index procedure . All patient continue receive aspirin indefinitely . The primary efficacy end point study incidence composite end point include cause death , myocardial infarction , incidence Academic Research Consortium define definite probable stent thrombosis stroke ( MACCE ) 24 month . The primary safety end point incidence GUSTO moderate severe bleed 24 month .</detailed_description>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Purinergic P2Y Receptor Antagonists</mesh_term>
	<criteria>Subjects 1880 year age Undergoing percutaneous intervention stent deployment treatment instent restenosis Pregnant woman Planned surgery necessitating discontinuation antiplatelet therapy within 24 month enrollment Current medical condition life expectancy &lt; 2 year Concurrent enrollment another device drug study whose protocol specifically rule concurrent enrollment Subjects warfarin similar anticoagulant therapy Subjects hypersensitivity allergies one drug Subjects unable give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Dual Antiplatelet Treatment</keyword>
	<keyword>In-Stent Restenosis</keyword>
</DOC>